Ticker brief · 2026-08-16
CAPR
FDA lifeline sparks rebound, but approval credibility remains deeply contested
Lean: mixedlast close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
62
authors 14d
35
crowd 14d
-0.1σ
CAPR remains mixed despite positive aggregate sentiment: regulatory-news accounts see a viable amended-BLA path, while the strongest fundamental voice expects rejection or another trial. The late-week shift was Tang Capital disclosing a 7.1% stake after Cantor moved to Overweight with a $28 target. A 30% short float, bullish options activity and event-driven buying create squeeze potential, but the structure remains subordinate to the August 22 FDA outcome.
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
BULL CAMP
Bulls argue FDA willingness to review supplemental extension data preserves a deramiocel approval path, while positive Phase 3 findings, Cantor support and concentrated capital strengthen the rerating case.
Key voices@PrismMarketViewMEDIUM-HIGHC@BPharmCatalystMEDIUM-HIGHC@BioStocksMEDIUM-HIGHC-3.02@wallstengineHIGHB-1.90
“FDA is willing to review an amended deramiocel BLA containing additional extension data.”— @PrismMarketView · tweet ↗
BEAR / SKEPTIC
Bears contend the 9-3 adverse vote, disputed efficacy analysis and lack of documentary FDA confirmation make rejection or a wholly new trial the more credible outcome.
Key voices@adamfeuersteinHIGHA+1.41@PharmdcaMEDIUM-HIGHC+0.82@InvestmentGuru_MEDIUMC+0.12@EmmanuelInvestLOW-MEDIUMC-1.11
“Capricor allegedly mischaracterized study data and still faces severe FDA approval obstacles.”— @adamfeuerstein · tweet ↗
Hypotheses10direction · basis · magnitude · supporters — NEW = first seen this week
▲FDA willingness to review an amended deramiocel BLA with extension data preserves a viable regulatory path despite the adverse panel vote.
@TT_stocks_LOW-MEDIUMC-0.671s@AlertsAndNewsLOW-MEDIUMC-1.901s@BriefingcomB+0.501s@PrismMarketViewMEDIUM-HIGHC1s@BPharmCatalystMEDIUM-HIGHC1s@PrismDMA-2.101s+2 more
▼The 9-3 adverse advisory vote materially lowers deramiocel approval odds and supports an FDA rejection by August 22.
@adamfeuersteinHIGHA+1.411s · insight@PharmdcaMEDIUM-HIGHC+0.821s@EmmanuelInvestLOW-MEDIUMC-1.111s@InvestmentGuru_MEDIUMC+0.121s@wallstengineHIGHB-1.901s
▼Capricor allegedly mischaracterized efficacy analyses, damaging management credibility and increasing the probability that FDA demands another clinical trial.
@adamfeuersteinHIGHA+1.414s · insight
▲Positive Phase 3 efficacy evidence preserves a substantive deramiocel approval case despite regulatory criticism of the underlying analysis.
@AlertsAndNewsLOW-MEDIUMC-1.901s@EmmanuelInvestLOW-MEDIUMC-1.111s@InvestmentGuru_MEDIUMC+0.121s@YYDSxjmLOW-MEDIUMB-0.511s
▲Cantor upgrading CAPR to Overweight with a $28 target provides sell-side validation despite modeling only 40% approval probability.
@BriefingcomB+0.501s@BioStocksMEDIUM-HIGHC-3.021s@Boytrader08LOW-MEDIUMC-0.941s@PharmdcaMEDIUM-HIGHC+0.821s@semodoughMEDIUM-HIGHC-3.011s
▲Halting non-deramiocel programs concentrates Capricor resources on securing FDA approval for its principal value-driving asset.
@Boytrader08LOW-MEDIUMC-0.941s
▲Tang Capital taking a 7.1% CAPR stake adds concentrated institutional sponsorship during the unresolved regulatory event.
@BioStocksMEDIUM-HIGHC-3.021s@zohmbasticMEDIUMC-1.381s
▲CAPR has established a tradable breakout structure, with support holds and heavy momentum creating additional near-term upside targets.
@MrGannabcLOW-MEDIUMC-0.452s@DekmarTradesMEDIUMC-1.241s@abc51648039LOW-MEDIUMC-1.292s@dmdt14LOW-MEDIUMC-1.881s
▲A 30% short float and unusual bullish options activity create conditions for event-driven upside acceleration or a squeeze.
◆A claimed strong earnings release drove CAPR up 121% to new highs, although no corroborating detail supports the attribution.
@DekmarTradesMEDIUMC-1.241s
Direct calls1authors taking explicit directional positions
@TT_stocks_LOW-MEDIUMC-0.67
Added CAPR shares and call options after the initial rally.
Sellside activity5
Cantor upgrade PT 28Upgraded CAPR to Overweight from Neutral.
Cantor upgrade PT 28Upgraded CAPR to Overweight and established a $28 price target.
Cantor pt_raise PT 28Raised its CAPR price target to $28.
Cantor target PT 28Published a $28 CAPR target.
Cantor noteReinstated its CAPR model using a 40% approval probability while acknowledging substantial residual risk.
News / data points5discrete events + data quoted by authors
@PrismMarketViewMEDIUM-HIGHC
FDA is willing to assess an amended deramiocel BLA using additional extension data.
@PharmdcaMEDIUM-HIGHC+0.82
The 9-3 negative advisory vote points toward likely FDA rejection by August 22.
@BriefingcomB+0.50
Cantor upgraded CAPR from Neutral to Overweight with a $28 target.
@BioStocksMEDIUM-HIGHC-3.02
Tang Capital disclosed a 7.1% CAPR stake.
@AlertsAndNewsLOW-MEDIUMC-1.90
Deramiocel remains under active FDA review after positive Phase 3 endpoint results.
Position disclosures1skin in the game
@TT_stocks_LOW-MEDIUMC-0.67
Reloaded CAPR shares and call options.
Desk readconvergence assessment
There is convergence that FDA engagement created a real regulatory lifeline, but no agreement that the new evidence is sufficient for approval. The credibility balance still favors skepticism: HIGH-credibility adamfeuerstein anchors the bear case, whereas much of the trading enthusiasm comes from LOW-MEDIUM accounts, including TT_stocks_, and Cantor coverage relayed by cold hands such as semodough at -2.33. Documentary FDA guidance, clarity on whether another trial is required, or the August 22 decision would resolve the disagreement.
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now -0.25 (−1 bearish … +1 bullish)
Who spoke35
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @TT_stocks_ | C | -0.67 | 8 | +0.56 |
| @BiopharmIQ | B | · | 6 | -0.22 |
| @OptionsFlowBoss | C | · | 5 | +0.25 |
| @adamfeuerstein | A | +1.41 | 5 | -0.62 |
| @BioStocks | C | -3.02 | 2 | +0.30 |
| @cnfinancewatch | B | -1.92 | 2 | +0.32 |
| @YYDSxjm | B | -0.51 | 2 | +0.57 |
| @PK_Fund | C | +0.11 | 2 | +0.72 |
| @PrismMarketView | C | · | 2 | -0.05 |
| @AlertsAndNews | C | -1.90 | 2 | -0.13 |
| @zohmbastic | C | -1.38 | 2 | +0.12 |
| @MikeJTrades | C | · | 1 | +0.30 |
| @dmdt14 | C | -1.88 | 1 | +0.25 |
| @DavidScottAdams | C | -1.92 | 1 | +0.00 |
| @Analytica_X | B | +1.03 | 1 | +0.00 |
| @abc51648039 | C | -1.29 | 1 | -0.20 |
| @kkernttb | C | -2.19 | 1 | +0.00 |
| @fundmyfund | B | -1.58 | 1 | +0.40 |
| @BoxTraderVK | C | -1.08 | 1 | +0.15 |
| @HejToJeMara | B | -1.43 | 1 | -0.50 |
| @EhrmantrautCap_ | C | -0.72 | 1 | -0.40 |
| @cfaryanoconnell | C | -1.48 | 1 | -0.10 |
| @ClassicRoy | C | -1.52 | 1 | -0.25 |
| @Pharmdca | C | +0.82 | 1 | +0.35 |
| @BPharmCatalyst | C | · | 1 | -0.20 |
Recent signals30of 62 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @PortfolioArmor | +0.00 | Weekly recap of exited trades and 204 fully closed trades year to date. | · | tweet ↗ |
| 2026-08-28 | @OzmosiHealth | -0.50 | Reports an FDA review extension amid a securities class action and lead-plaintiff deadline. | · | tweet ↗ |
| 2026-08-26 | @A_Najumi | +0.20 | Lists the day's highest-volume call contracts with strikes, expiries and dollar notionals. | · | tweet ↗ |
| 2026-08-26 | @PrismMarketView | +0.40 | Summarizes sector-index and single-stock moves with exact daily percentages. | · | tweet ↗ |
| 2026-08-26 | @FL0WG0D | +0.40 | Reports $1M of CAPR call buying. | · | tweet ↗ |
| 2026-08-25 | @Blaine_Tarr | +0.65 | Discloses ownership of CAPR shares while suggesting another upward leg may come soon. | · | tweet ↗ |
| 2026-08-25 | @Boytrader08 | +0.50 | Suggests CAPR may begin a second upward round after a strong close. | · | tweet ↗ |
| 2026-08-25 | @OptionsFlowBoss | +0.45 | Lists unusual bullish options-volume multiples; ticker output capped at six. | · | tweet ↗ |
| 2026-08-25 | @Maximus_Holla | -0.30 | Cover CAPR ahead of PDUFA. — Explicitly calls for covering CAPR exposure around the pending PDUFA catalyst. | · | tweet ↗ |
| 2026-08-25 | @OptionsFlowBoss | +0.00 | Reports unusual CAPR options activity without stating direction. | · | tweet ↗ |
| 2026-08-25 | @zohmbastic | +0.40 | Oppenheimer upgrades CAPR to Outperform from Perform with a $54 target. | · | tweet ↗ |
| 2026-08-25 | @OpenOutcrier | +0.40 | Daily analyst-action list reports upgrades; extraction is capped at the first six directly affected tickers. | · | tweet ↗ |
| 2026-08-25 | @PK_Fund | +0.65 | Celebratory 'boom' reaction conveys bullish CAPR sentiment. | · | tweet ↗ |
| 2026-08-24 | @11thestate | -0.30 | Reports an active case against CAPR that may allow investors to recover losses. | · | tweet ↗ |
| 2026-08-24 | @fwpharma | +0.00 | FDA set a November decision date for Capricor's DMD therapy. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.30 | Summarizes four biotech regulatory or clinical catalysts and corresponding price moves. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.15 | Dense biotech list reports trial, PDUFA, filing and approval developments with market moves. | · | tweet ↗ |
| 2026-08-24 | @OptionsFlowBoss | +0.40 | Lists unusual bullish options-volume multiples during the first two trading hours. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.30 | Reports FDA extending deramiocel's PDUFA date from August 22 to November 22, 2026. | · | tweet ↗ |
| 2026-08-24 | @BPharmCatalyst | -0.20 | FDA extends the PDUFA action date for deramiocel from August 22 to November 22, 2026. | · | tweet ↗ |
| 2026-08-24 | @Pharmdca | +0.35 | Reports a new November 22, 2026 PDUFA action date after additional Phase 3 data. | · | tweet ↗ |
| 2026-08-24 | @zohmbastic | -0.15 | FDA extended the Deramiocel BLA action date from August 22 to November 22, 2026. | · | tweet ↗ |
| 2026-08-24 | @adamfeuerstein | +0.50 | CAPR avoided an immediate deramiocel rejection and received a new Nov. 22 PDUFA date. | · | tweet ↗ |
| 2026-08-24 | @AlertsAndNews | -0.10 | Reports the November 22, 2026 PDUFA date following additional Phase 3 data and analyses. | · | tweet ↗ |
| 2026-08-24 | @AlertsAndNews | -0.15 | Capricor announced an extension of the PDUFA action date during FDA review of Deramiocel. | · | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | -0.35 | Provides a watch list of four imminent FDA decisions and their investor setups. | · | tweet ↗ |
| 2026-08-23 | @cnfinancewatch | +0.00 | Lists dated FDA approvals and upcoming PDUFA decisions across a biotech catalyst basket. | · | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | +0.00 | Reports MRNA's 177% move on positive Phase 3 endpoints and lists upcoming biotech catalysts. | · | tweet ↗ |
| 2026-08-21 | @BioStocks | +0.30 | Kaos Capital demanded an immediate shareholder meeting, board change and capital-preservation plan. | · | tweet ↗ |
| 2026-08-20 | @adamfeuerstein | -0.90 | Accuses Capricor of altering endpoints and misrepresenting statistical significance, with worse pulmonary data. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.